The effect of intravitreal bevacizumab (Avastin®) on ocular pulse amplitude in neovascular age-related macular degeneration
| Autor: | Ingeborg Stalmans, Alon Harris, Joseph Glovinsky, Joachim Van Calster, Ehud Rechtman, Joseph Moisseiev, Christophe Breusegem |
|---|---|
| Přispěvatelé: | Ophtalmology - Eye surgery |
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
macular degeneration genetic structures Bevacizumab Hemodynamics bevacizumab Ophthalmology Age related medicine blood flow Intravitreal bevacizumab Original Research Medicine(all) ocular pulse amplitude business.industry Clinical Ophthalmology Blood flow Macular degeneration medicine.disease eye diseases medicine.anatomical_structure sense organs Choroid business choroid medicine.drug |
| Zdroj: | Clinical Ophthalmology (Auckland, N.Z.) |
| ISSN: | 1177-5483 |
| DOI: | 10.2147/opth.s15810 |
| Popis: | Ehud Rechtman1, Ingeborg Stalmans2, Joseph Glovinsky1, Christophe Breusegem2, Joseph Moisseiev1, Joachim Van Calster2, Alon Harris31Goldschleger Eye Institute, Sheba Medical Center, Ramat Gan, Israel; 2Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium; 3Department of Ophthalmology, Indiana University, Indianapolis, IN, USAPurpose: To evaluate the effect of intravitreal (IVT) bevacizumab in neovascular age-related macular degeneration (AMD) on global choroidal hemodynamics, as measured by ocular pulse amplitude (OPA).Methods: This was a two-center prospective study (Sheba Medical Center, Israel, and University Hospitals Leuven, Belgium). AMD patients who required IVT bevacizumab (1.25 mg/0.05 mL; first or repeated) were examined three times: at days 0 (prior to injection), 7 (±3), and 28 (±7) postinjection. At each visit, OPAs of both eyes were measured using the Pascal dynamic contour tonometer (DCT). A paired t-test between preoperative and postoperative OPA was conducted. Pearson correlation was used to evaluate the influence of various measured parameters on DCT–OPA.Results: A total of 38 neovascular AMD patients were recruited, and 30 patients were included in the final analysis (18 females and 12 males; age 78.8 ± 5.82 years [mean ± standard deviation]). A good correlation was found throughout the study between the DCT–intraocular pressure (IOP) and Goldmann IOP and between DCT–IOP and DCT–OPA. No change in OPA of bevacizumab-treated eyes was found between the visits (2.24 ± 0.73, 2.2 ± 0.86, and 2.23 ± 0.73 mm Hg at visits 1, 2, and 3, respectively; paired t-test: P = 0.77 between visits 1 and 2, P = 0.98 between visits 1 and 3). No correlations were found between DCT–OPA and age, heart rate, systemic blood pressure, axial length, keratometry readings, and central corneal thickness.Conclusions: OPA, an indirect measure of global choroidal hemodynamics, remains unchanged following IVT off-label bevacizumab. This finding adds to the growing evidence regarding the safety profile of bevacizumab in AMD treatment.Keywords: macular degeneration, choroid, blood flow, ocular pulse amplitude, bevacizumab |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|